Patents by Inventor Erin Lavik
Erin Lavik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404934Abstract: A long-term delivery system for age-related macular degeneration (AMD) that can address the multifactorial nature of the disease. A polyurethane nanocapsule is disclosed that includes encapsulated molecules that treat AMD. The molecules can be passively delivered from the polyurethane nanocapsules over many weeks or months and/or can be tuned, non-invasively, using ultrasound to trigger the release the molecules from the polyurethane nanocapsules repeatedly in an on-demand and predictable manner. These nanocapsules have the potential to change the way diseases are treated and provide a new ultrasound-triggered drug delivery platform.Type: ApplicationFiled: April 12, 2023Publication date: December 21, 2023Inventors: Erin LAVIK, Sydney MENIKHEIM, Joshua LECKRON
-
Patent number: 11821893Abstract: A process of simply, cheaply, and reproducibly creating complex tissue models using screen printing and the tissue model prepared using the screen printing process. These models are amenable to high throughput screening. They will allow the study of components of disease progression and can be used for screening therapies.Type: GrantFiled: February 23, 2021Date of Patent: November 21, 2023Assignees: University of Maryland, Baltimore County, University of Maryland, BaltimoreInventors: Erin Lavik, Steve Bernstein, Adam Day, Bryan Ibarra
-
Publication number: 20230018837Abstract: One of the significant challenges to translation of intravenously administered nanomaterials has been complement-mediated infusion reactions which can be lethal. Slow infusions can reduce infusion reactions, but slow infusions are not always possible in applications like controlling bleeding following trauma. Nanocapsules based on polyurethane are introduced as candidates that do not substantially activate complement protein C5a and the PEGylation and functionalization of the nanocapsules with the GRGDS peptide to create a new class of hemostatic nanomaterials is disclosed. Advantageously, the nanocapsules substantially avoid complement-mediated infusion reactions, promote faster clotting than controls, maintain maximum clot firmness, and do not activate pro-inflammatory cytokines.Type: ApplicationFiled: July 15, 2022Publication date: January 19, 2023Inventors: Erin LAVIK, Nuzhat MAISHA
-
Publication number: 20210172933Abstract: A process of simply, cheaply, and reproducibly creating complex tissue models using screen printing and the tissue model prepared using the screen printing process. These models areamenable to high throughput screening. They will allow the study of components of disease progression and can be used for screening therapies.Type: ApplicationFiled: February 23, 2021Publication date: June 10, 2021Inventors: Erin LAVIK, Steve BERNSTEIN, Adam DAY, Bryan IBARRA
-
Patent number: 11002727Abstract: A process of simply, cheaply, and reproducibly creating complex tissue models using screen printing and the tissue model prepared using the screen printing process. These models are amenable to high throughput screening. They will allow the study of components of disease progression and can be used for screening therapies.Type: GrantFiled: July 27, 2018Date of Patent: May 11, 2021Assignees: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Erin Lavik, Steve Bernstein, Adam Day, Bryan Ibarra
-
Publication number: 20190187128Abstract: A process of simply, cheaply, and reproducibly creating complex tissue models using screen printing and the tissue model prepared using the screen printing process. These models are amenable to high throughput screening. They will allow the study of components of disease progression and can be used for screening therapies.Type: ApplicationFiled: July 27, 2018Publication date: June 20, 2019Inventors: Erin LAVIK, Steve BERNSTEIN, Adam DAY, Bryan IBARRA
-
Patent number: 9962462Abstract: The invention provides for dry spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide.Type: GrantFiled: June 13, 2016Date of Patent: May 8, 2018Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: Erin Lavik
-
Publication number: 20170043051Abstract: The invention provides for dry spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide.Type: ApplicationFiled: June 13, 2016Publication date: February 16, 2017Inventor: Erin Lavik
-
Publication number: 20160310615Abstract: The invention provides for spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide and a delivery solvent. The present invention provides for spray hemostatic systems that allow for quick and even distribution of hemostatic nanoparticles or synthetic platelets that reducing bleeding and improve outcomes in trauma. The invention provides for spray compositions comprising a co-block polymer coupled to a water soluble polymer, and a polymer delivery solvent. The invention provides for spray compositions which comprise nanoparticles that halve bleeding time in a femoral artery injury model, which allow for even distribution of the nanoparticles at a wound site and allow application to areas that are difficult to contact with other methods of administration.Type: ApplicationFiled: December 11, 2014Publication date: October 27, 2016Inventor: Erin LAVIK
-
Publication number: 20160101054Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (IOP) in the eye.Type: ApplicationFiled: April 28, 2014Publication date: April 14, 2016Inventors: ERIN LAVIK, JAMES BERTRAM, SANDEEP SALUJA, MARKUS KUEHN, JOHN J. HUANG, REBECCA ROBINSON, YOUNG H. KWON
-
Publication number: 20160081932Abstract: The invention provides for compositions comprising nanoparticles comprising a core, water-soluble polymer and an RGD peptide and a poloxamer.Type: ApplicationFiled: April 15, 2014Publication date: March 24, 2016Applicant: CASE WESTERN RESERVE UNIVERSITYInventor: Erin Lavik
-
Publication number: 20160000973Abstract: The invention provides for the development of reporter scaffolds comprising sustained release reporter molecules and methods of using these scaffolds to administer therapeutic agent and/or monitor the effect of the transplant on the surrounding tissue or monitoring the status or condition of transplanted cells over time after the scaffold is in place.Type: ApplicationFiled: July 7, 2015Publication date: January 7, 2016Inventor: Erin Lavik
-
Publication number: 20140242180Abstract: A temperature stable nanoparticle is provided comprising a core, a water soluble polymer and a peptide, the water soluble polymer attached to the core at a first terminus of the water soluble polymer, the peptide attached to a second terminus of the water soluble polymer, the peptide comprising an RGD amino acid sequence, the water soluble polymer of having sufficient length to allow binding of the peptide to glycoprotein lib/Ilia (GPIIb/llla). In one aspect, the nanoparticle has a melting temperature over 35° C. In various aspects, the nanoparticle has a spheroid shape and a diameter of less than 1 micron.Type: ApplicationFiled: October 12, 2012Publication date: August 28, 2014Inventors: Erin Lavik, Andrew Shoffstall, Jeffrey Ustin
-
Publication number: 20130316010Abstract: A pharmaceutical composition is provided comprising microparticles encapsulating high weight percent active agent and providing sustained release over a prolonged period of time of active agent levels bioequivalent to direct administration of active agent. Polymeric microparticle compositions containing one or more active agents, and methods of making and using thereof, are described. The microparticles are optimized for the agent to be delivered, so that the hydrophobicity or hydrophilicity of the polymer and charge of the polymer maximizes loading of the agent, and the selection and molecular weight of the polymers maximize release of an effective amount of the active agent for the desired period of time.Type: ApplicationFiled: October 18, 2011Publication date: November 28, 2013Applicant: Case Western Reserve UniversityInventor: Erin Lavik
-
Patent number: 8492334Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing one or more diseases or disorders of the eye, and methods of making and using thereof, are described. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (IOP) in the eye. Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time.Type: GrantFiled: June 18, 2008Date of Patent: July 23, 2013Assignees: Yale University, University of Iowa Research FoundationInventors: Erin Lavik, Young H. Kwon, Markus Kuehn, Sandeep Saluja, James Bertram, John Huang
-
Publication number: 20110206773Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye.Type: ApplicationFiled: November 12, 2010Publication date: August 25, 2011Inventors: Erin Lavik, James Bertram, Sandeep Saluja, Markus Kuehn, Young H. Kwon, Rebecca Robinson, John J. Huang
-
Publication number: 20100261646Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”).Type: ApplicationFiled: June 18, 2008Publication date: October 14, 2010Applicants: YALE UNIVERSITY, UNIVERISTY OF IOWA RESEARCH FOUNDATIONInventors: Erin Lavik, Young H. Kwon, Markus Kuehn, Sandeep Saluja, James Bertram, John Huang
-
Publication number: 20050031598Abstract: A method of producing a tissue engineering construct. The method includes providing a population of embryonic stem cells, seeding the embryonic stem cells on a cell support matrix, and exposing the embryonic stem cells to at least one agent selected to promote differentiation of the stem cells along a predetermined cell lineage or into a specific cell type. The step of exposing may be performed before or after the step of seeding.Type: ApplicationFiled: December 9, 2003Publication date: February 10, 2005Inventors: Shulamit Levenberg, Ngan Huang, Erin Lavik, Joseph Itskovitz-Eldor, Robert Langer